BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33941587)

  • 1. T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models.
    Morello G; Cancila V; La Rosa M; Germano G; Lecis D; Amodio V; Zanardi F; Iannelli F; Greco D; La Paglia L; Fiannaca A; Urso AM; Graziano G; Ferrari F; Pupa SM; Sangaletti S; Chiodoni C; Pruneri G; Bardelli A; Colombo MP; Tripodo C
    Cancer Immunol Res; 2021 Jul; 9(7):825-837. PubMed ID: 33941587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.
    Park IA; Rajaei H; Kim YA; Lee H; Lee H; Seo JH; Heo SH; Song IH; Gong G; Lee HJ
    Immunol Res; 2020 Oct; 68(5):233-245. PubMed ID: 32886262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8
    Melssen MM; Lindsay RS; Stasiak K; Rodriguez AB; Briegel AM; Cyranowski S; Rutkowski MR; Conaway MR; Melief CJM; van der Burg SH; Eyo U; Slingluff CL; Engelhard VH
    Cancer Immunol Res; 2021 May; 9(5):583-597. PubMed ID: 33619119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional HPV-specific PD-1
    Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
    Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer.
    Solis-Castillo LA; Garcia-Romo GS; Diaz-Rodriguez A; Reyes-Hernandez D; Tellez-Rivera E; Rosales-Garcia VH; Mendez-Cruz AR; Jimenez-Flores JR; Villafana-Vazquez VH; Pedroza-Gonzalez A
    Breast Cancer; 2020 Sep; 27(5):837-849. PubMed ID: 32180141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
    Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
    Nature; 2021 Aug; 596(7870):126-132. PubMed ID: 34290408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse PVRIG Has CD8
    Murter B; Pan X; Ophir E; Alteber Z; Azulay M; Sen R; Levy O; Dassa L; Vaknin I; Fridman-Kfir T; Salomon R; Ravet A; Tam A; Levin D; Vaknin Y; Tatirovsky E; Machlenkin A; Pardoll D; Ganguly S
    Cancer Immunol Res; 2019 Feb; 7(2):244-256. PubMed ID: 30659055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
    Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
    Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
    Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
    Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
    Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
    Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.
    Zhu L; Narloch JL; Onkar S; Joy M; Broadwater G; Luedke C; Hall A; Kim R; Pogue-Geile K; Sammons S; Nayyar N; Chukwueke U; Brastianos PK; Anders CK; Soloff AC; Vignali DAA; Tseng GC; Emens LA; Lucas PC; Blackwell KL; Oesterreich S; Lee AV
    J Immunother Cancer; 2019 Oct; 7(1):265. PubMed ID: 31627744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.